GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Investments And Advances

NGNE (Neurogene) Investments And Advances : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Investments And Advances?

Neurogene's Investments And Advances for the quarter that ended in Dec. 2024 was $0.00 Mil.


Neurogene Investments And Advances Historical Data

The historical data trend for Neurogene's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Investments And Advances Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Investments And Advances
- - - -

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Neurogene Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Neurogene Business Description

Traded in Other Exchanges
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.